Global Biologics CDMO Market - A Global and Regional Analysis, 2023-2033

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,950	165 Pages	BIS Research	November, 2023	BIS18306082

Best Price Guarantee
Price	from $4,950
Length	165 Pages
Publisher	BIS Research
Published Date	November, 2023
SKU	BIS18306082

Global Biologics CDMO Market - A Global and Regional Analysis, 2023-2033

Biologics CDMO Industry Overview

The global biologics CDMO market was valued at $XX billion in 2022 and is anticipated to reach $XX billion by 2033, witnessing a CAGR of XX% during the forecast period 2023-2033.

Introduction to Biologics CDMO Market

The global biologics CDMO market plays a crucial role in the pharmaceutical and biotechnology industries, offering specialized services for the development, manufacturing, and testing of biologic drugs. Biologics are complex molecules derived from living organisms, such as proteins, antibodies, and nucleic acids, and they have become increasingly important in the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases.

CDMOs in the biologics sector provide a range of services, including cell line development, process development, scale-up, manufacturing, quality control, and regulatory support. These organizations serve as strategic partners for pharmaceutical and biotech companies, allowing them to outsource certain aspects of the drug development and manufacturing process, thereby gaining efficiency, expertise, and flexibility.

Market Segmentation:

Segmentation 1: by Cell Type

Mammalian
Non-mammalian

Segmentation 2: by Product Type

Biologics
Monoclonal Antibodies
Recombinant Proteins
Antisense and Molecular Therapy
Vaccines
Other Biologics
Biosimilars

Segmentation 3: by Region

North America
Europe
Asia-Pacific
Latin America
MEA

The report provides data for each of these regions, with in-depth country-level analyses, all covering the period from 2022 to 2033.

How can this report add value to an organization?

Product/Innovation Strategy: The global biologics CDMO market has been extensively segmented based on various categories, such as cell type and product type. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Growth/Marketing Strategy: The global biologics CDMO market has seen major development by key players operating in the market, such as business expansion, partnership, collaboration, and joint venture.

Competitive Strategy: Key players in the global biologics CDMO market analyzed and profiled in the study involve established and emerging players. Moreover, a detailed competitive benchmarking of the players operating in the global biologics CDMO market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analysing company coverage, product portfolio, and market penetration.

Some of the prominent names established in this market are:

Boehringer Ingelheim Group
Lonza Group
Samsung Biologics
NOVARTIS AG
Toyobo Co. Limited
Parexel International Corporation
Catalent Inc.
Binex Co. Limited
AGC Biologics
AbbVie Contract Manufacturing

*PDF email from publisher allows for 1-3 users, with permission to print*

Please Note: It will take 2-3 business days to complete the report upon order confirmation.

1 Markets: Industry Outlook: 1.1 Trends: Current and Future Impact Assessment; 1.1.1 Emerging Gene and Cell Therapies; 1.1.2 Single-use Bioprocessing Equipment; 1.1.3 Trend Toward Personalized Medicine; 1.2 Supply Chain Overview; 1.2.1 Value chain Analysis; 1.2.2 Market Map; 1.2.3 Cost of Manufacturing in CDMO/gm Forecast; 1.3 Patent Analysis; 1.3.1 Awaited Technological Developments; 1.3.2 Patent Filing Trend by Country, by Year; 1.3.3 Patent Filing Trend by Country, by Country; 1.4 Regulatory Landscape; 1.5 Prodution Capacity; 1.6 Factors Considered While Outsourcing To CDMO; 1.7 Impact analysis for key global events- covid19, Russia/Ukraine or Middle East crisis; 1.8 Market Dynamics Overview; 1.8.1 Market Drivers; 1.8.2 Market Restraints; 1.8.3 Market Opportunities
2 Application: 2.1 Application Segmentation; 2.2 Application Summary; 2.3 Global Biologiv CDMO Market (by Cell Type); 2.3.1 Mammalian; 2.3.2 Non-mammalian
3 Product: 3.1 Product Segmentation; 3.2 Product Summary; 3.3 Global Biologics CDMO Market (by Product Type); 3.3.1 Biologics; 3.3.1.1 Monoclonal Antibodies; 3.3.1.2 Recombinant Proteins; 3.3.1.3 Antisense and Molecular Therapy; 3.3.1.4 Vaccines; 3.3.1.5 Other Biologics; 3.3.2 Biosimilars
4 Region: 4.1 Regional Summary; Table: Biologics CDMO Market, By Region, ($ Million), 2022-2033; 4.2 Drivers and Restraints; 4.3 North America; Key Market Participants in North America; Business Drivers; Business Challenges; 4.3.1 Application; Table: North America Biologics CDMO Market, By Cell Type ($ Million), 2022-2033; 4.3.2 Product; Table: North America Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033; 4.3.3 North America (by Country); 4.3.3.1 U.S.; Table: U.S. Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033; Table: U.S. Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033; 4.3.3.2 Canada; Table: U.S. Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033; Table: U.S. Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033; 4.4 Europe; Key Market Participants in Europe; Business Drivers; Business Challenges; 4.4.1 Application; Table: Europe Biologics CDMO Market, By Cell Type ($ Million), 2022-2033; 4.4.2 Product; Table: Europe Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033; 4.4.3 Europe (by Country); 4.4.3.1 U.K.; Table: U.K.Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033; Table: U.K. Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033; 4.4.3.2 Germany; Table: Germany Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033; Table: Germany Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033; 4.4.3.3 Italy; Table: Italy Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033; Table: Italy Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033; 4.4.3.4 France; Table: France Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033; Table: France Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033; 4.4.3.5 Spain; Table: Spain Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033; Table: Spain Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033; 4.4.3.6 Rest of Europe; Table: Rest of Europe Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033; Table: Rest of Europe Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033; 4.5 Asia Pacific; Key Market Participants in Asia Pacific; Business Drivers; Business Challenges; 4.5.1 Application; Table: Europe Biologics CDMO Market, By Cell Type ($ Million), 2022-2033; 4.5.2 Product; Table: Europe Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033; 4.5.3 Asia Pacific (by Country); 4.5.3.1 China; Table: China Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033; Table: China Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033; 4.5.3.2 Japan; Table: Japan Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033; Table: Japan Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033; 4.5.3.3 India; Table: India Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033; Table: India Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033; 4.5.3.4 Australia; Table: Australia Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033; Table: Australia Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033; 4.5.3.5 Rest of APAC; Table: Rest of APAC Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033; Table: Rest of APAC Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033; 4.6 Latin America; Key Market Participants in Latin America; Business Drivers; Business Challenges; 4.6.1 Application; Table: Latin America Biologics CDMO Market, By Cell Type ($ Million), 2022-2033; 4.6.2 Product; Table: Latin America Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033; 4.6.3 Latin America (by Country); 4.6.3.1 Brazil; Table: Brazil Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033; Table: Brazil Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033; 4.6.3.2 Mexico; Table: Mexico Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033; Table: Mexico Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033; 4.6.3.3 Rest of Latin America; Table: Rest of Latin America Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033; Table: Rest of Latin America Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033; 4.7 MEA; Key Market Participants in MEA; Business Drivers; Business Challenges; 4.7.1 Application; Table: MEA Biologics CDMO Market, By Cell Type ($ Million), 2022-2033; 4.7.2 Product; Table: MEA Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033; 4.7.3 MEA (by Country); 4.7.3.1 Saudi Arabia; Table: Saudi Arabia Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033; Table: Saudi Arabia Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033; 4.7.3.2 U.A.E.; Table: U.A.E. Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033; Table: U.A.E. Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033; 4.7.3.3 Rest of MEA; Table: Rest of MEA Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033; Table: Rest of MEA Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
5 Markets - Competitive Landscape & Company Profiles: 5.1 Competitive Landscape; 5.2 Company Profile; 5.2.1 Boehringer Ingelheim Group; 5.2.1.1 Company Overview; 5.2.1.1.1 Role of Boehringer Ingelheim Group in Biologics CDMO Market; 5.2.1.1.2 Product Portfolio; 5.2.1.2 Business Strategies; 5.2.1.3 Corporate Strategies; 5.2.1.4 Analyst View; 5.2.2 Lonza Group; 5.2.2.1 Company Overview; 5.2.2.1.1 Role of Lonza Group in Biologics CDMO Market; 5.2.2.1.2 Product Portfolio; 5.2.2.2 Business Strategies; 5.2.2.3 Corporate Strategies; 5.2.2.4 Analyst View; 5.2.3 Samsung Biologics; 5.2.3.1 Company Overview; 5.2.3.1.1 Role of Samsung Biologics in Biologics CDMO Market; 5.2.3.1.2 Product Portfolio; 5.2.3.2 Business Strategies; 5.2.3.3 Corporate Strategies; 5.2.3.4 Analyst View; 5.2.4 NOVARTIS AG; 5.2.4.1 Company Overview; 5.2.4.1.1 Role of NOVARTIS AG in Biologics CDMO Market; 5.2.4.1.2 Product Portfolio; 5.2.4.2 Business Strategies; 5.2.4.3 Corporate Strategies; 5.2.4.4 Analyst View; 5.2.5 Toyobo Co. Limited; 5.2.5.1 Company Overview; 5.2.5.1.1 Role of Toyobo Co. Limited Group in Biologics CDMO Market; 5.2.5.1.2 Product Portfolio; 5.2.5.2 Business Strategies; 5.2.5.3 Corporate Strategies; 5.2.5.4 Analyst View; 5.2.6 Parexel International Corporation; 5.2.6.1 Company Overview; 5.2.6.1.1 Role of Parexel International Corporation in Biologics CDMO Market; 5.2.6.1.2 Product Portfolio; 5.2.6.2 Business Strategies; 5.2.6.3 Corporate Strategies; 5.2.6.4 Analyst View; 5.2.7 Catalent Inc.; 5.2.7.1 Company Overview; 5.2.7.1.1 Role of Catalent Inc. in Biologics CDMO Market; 5.2.7.1.2 Product Portfolio; 5.2.7.2 Business Strategies; 5.2.7.3 Corporate Strategies; 5.2.7.4 Analyst View; 5.2.8 Binex Co. Limited; 5.2.8.1 Company Overview; 5.2.8.1.1 Role of Binex Co. Limited in Biologics CDMO Market; 5.2.8.1.2 Product Portfolio; 5.2.8.2 Business Strategies; 5.2.8.3 Corporate Strategies; 5.2.8.4 Analyst View; 5.2.9 AGC Biologics; 5.2.9.1 Company Overview; 5.2.5.1.1 Role of AGC Biologics in Biologics CDMO Market; 5.2.5.1.2 Product Portfolio; 5.2.9.2 Business Strategies; 5.2.9.3 Corporate Strategies; 5.2.9.4 Analyst View; 5.2.10 AbbVie Contract Manufacturing; 5.2.10.1 Company Overview; 5.2.10.1.1 Role of AbbVie Contract Manufacturing in Biologics CDMO Market; 5.2.10.1.2 Product Portfolio; 5.2.10.2 Business Strategies; 5.2.10.3 Corporate Strategies; 5.2.10.4 Analyst View